Nature Biotechnology's annual survey of public biotechnology companies reveals the effect of straitened financial circumstances on R&D budgets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Lähteenmäki, R., Hodgson, J. Public biotech 99: the numbers. Nat Biotechnol 18, 499–503 (2000). https://doi.org/10.1038/75355
Issue Date:
DOI: https://doi.org/10.1038/75355
This article is cited by
-
Public biotech 2000—the numbers
Nature Biotechnology (2001)